Last reviewed · How we verify
London North West Healthcare NHS Trust — Portfolio Competitive Intelligence Brief
3 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Tagitol V, Lo So, Readi-Cat 2 | Tagitol V, Lo So, Readi-Cat 2 | marketed | ||||
| Diamorphine or Morphine | Diamorphine or Morphine | marketed | Opioid agonist | Mu opioid receptor (OPRM1) | Pain management | |
| oestradiol | oestradiol | marketed | Other | |||
| Citramag powder | Citramag powder | phase 3 | Osmotic laxative | Gastroenterology |
Therapeutic area mix
- Gastroenterology · 1
- Other · 1
- Pain management · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Aboca Spa Societa' Agricola · 1 shared drug class
- Ahmed M Maged, MD · 1 shared drug class
- Ain Shams University · 1 shared drug class
- Amsterdam UMC, location VUmc · 1 shared drug class
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- Azienda Policlinico Umberto I · 1 shared drug class
- Bayer · 1 shared drug class
- Aarhus University Hospital · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for London North West Healthcare NHS Trust:
- London North West Healthcare NHS Trust pipeline updates — RSS
- London North West Healthcare NHS Trust pipeline updates — Atom
- London North West Healthcare NHS Trust pipeline updates — JSON
Cite this brief
Drug Landscape (2026). London North West Healthcare NHS Trust — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/london-north-west-healthcare-nhs-trust. Accessed 2026-05-17.